Avantor (NYSE:AVTR) Posts Earnings Results

Avantor (NYSE:AVTR) issued its earnings results on Wednesday. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01, FiscalAI reports. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company earned $0.22 EPS. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year.

Here are the key takeaways from Avantor’s conference call:

• Avantor returned to organic revenue growth in Q3, with revenue up 5.2% organically to $1.698 billion. VWR grew 5.8%, while Bioscience & Medtech Products returned to growth at 3.6%, supported by improved execution and stronger demand.
• Management raised its 2026 outlook, now expecting organic revenue growth of 0.75%–1.25%, adjusted EPS of $0.81–$0.83, and free cash flow of $525–$550 million. The company expects adjusted net leverage to fall below 3.0x by year-end, compared with 3.1x at the end of Q3.
• The company cited continued momentum from its Revival program, including improved manufacturing throughput, supply-chain execution, customer service, e-commerce, and AI-enabled commercial tools. BMP also reported positive book-to-bill trends and strong performance in Process Chemicals and NuSil.
• Profitability remains pressured by product and customer mix, inflation, and targeted growth investments, particularly in VWR. Management said 2026 pricing of roughly 1%–2% has not fully offset inflation, while Europe remains a weak market and BMP faces approximately 400 basis points of discrete comparison headwinds in Q4.

Avantor Price Performance

Shares of NYSE:AVTR traded up $0.01 on Thursday, hitting $16.70. The company’s stock had a trading volume of 4,674,498 shares, compared to its average volume of 10,192,147. Avantor has a 1 year low of $7.26 and a 1 year high of $17.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18. The company has a market capitalization of $11.30 billion, a PE ratio of -19.90, a PEG ratio of 9.83 and a beta of 0.94. The company has a 50-day simple moving average of $15.40 and a 200 day simple moving average of $11.20.

Trending Headlines about Avantor

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Avantor reported third-quarter sales of $1.698 billion, up 4.6% year over year and ahead of the $1.64 billion consensus estimate. Organic growth was 5.2%, with both major segments returning to growth. Avantor Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted earnings of $0.22 per share exceeded analysts’ $0.21 estimate, while GAAP diluted EPS was $0.30. Results also matched the prior-year adjusted EPS despite the company’s ongoing business transition. Avantor Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its full-year 2026 organic revenue-growth, adjusted EPS and free-cash-flow guidance, improving the outlook for future earnings and cash generation. Avantor Guidance Update
• Positive Sentiment: Robert W. Baird raised its price target from $17 to $18 and maintained an “outperform” rating. Stifel Nicolaus also lifted its target from $15 to $18, though it retained a “hold” rating. Baird Raises Avantor Price Target
• Neutral Sentiment: The earnings beat was modest, and adjusted EPS was unchanged from a year earlier. Investors may therefore look for evidence that the improved growth trend can translate into sustained profitability.
• Negative Sentiment: Barclays kept a “sell” rating and a $15 price target, highlighting a more cautious view of Avantor’s valuation and business outlook. The company also continues to report a negative net margin. Barclays Maintains Sell Rating

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a $17.00 target price on shares of Avantor in a report on Wednesday. Morgan Stanley increased their target price on shares of Avantor from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 13th. UBS Group assumed coverage on Avantor in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $16.00 price target on the stock. Wall Street Zen raised shares of Avantor from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $17.00 price target on shares of Avantor in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $14.59.

About Avantor

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.